737 results on '"Latagliata, R"'
Search Results
2. Aggressive systemic mastocytosis with the co-occurrence of PRKG2::PDGFRB, KAT6A::NCOA2, and RXRA::NOTCH1 fusion transcripts and a heterozygous RUNX1 frameshift mutation
3. The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
4. Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: THE GENE EXPRESSION PROFILE OF GENES BELONGING TO TRANSFORMING GROWTH FACTOR-B PATHWAY IS DEREGULATED IN SF3B1 MUTATED LOW-RISK MDS PATIENTS
5. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
6. Differences among young adults, adults and elderly chronic myeloid leukemia patients
7. P061 - Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: THE GENE EXPRESSION PROFILE OF GENES BELONGING TO TRANSFORMING GROWTH FACTOR-B PATHWAY IS DEREGULATED IN SF3B1 MUTATED LOW-RISK MDS PATIENTS
8. JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy
9. P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB
10. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis
11. Is There a Role for Bone Marrow Biopsy In The Diagnosis of Masked Polycythemia Vera with Splanchnic Vein Thrombosis?
12. Differences among young adults, adults and elderly chronic myeloid leukemia patients
13. Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal
14. Analisi costo-efficacia di dasatinib nella prospettiva del SSN italiano
15. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
16. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features
17. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome
18. High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias
19. Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols
20. Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen
21. Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon
22. Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy
23. Persistence of BCR-ABL1 gene signal in 10-year survivors of myeloablative allogeneic haematopoietic stem cell transplantation for chronic myeloid leukaemia: P722
24. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971–1991)
25. Management of infective complications in patients with advanced hematologic malignancies in home care
26. Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes
27. BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results
28. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib
29. Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia
30. Intraventricular thrombosis during all-trans retinoic acid treatment in acute promyelocytic leukemia
31. Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes
32. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia
33. PF674 OUTCOME OF PATIENTS WITH MYELOFIBROSIS AFTER RUXOLITINIB DISCONTINUATION: ROLE OF DISEASE STATUS AND TREATMENT STRATEGIES IN 218 PATIENTS
34. PS1172 DDPCR AT THE TIME OF TKI DISCONTINUATION IN CHRONIC PHASE CHRONIC MYELOID PATIENTS IS PREDICTIVE OF TREATMENT-FREE REMISSION OUTCOME
35. Management and outcome of 11 pregnancies in women with polycythemia vera
36. PS1343 ARE MYELODYSPLASTIC SYNDROMES WITH ISOLATED 20Q DELETION A DIFFERENT CLINICAL‐BIOLOGICAL ENTITY?
37. HIGH LEVELS OF APOPTOSIS CHARACTERIZE RAEB AND ARE LOST DURING LEUKEMIC TRANSFORMATION
38. Treatment of high-risk myelodysplastic syndromes with lymphoblastoid alpha interferon
39. Second Generation Tyrosine Kinase Inhibitors (2G-TKI) in the Frontline Treatment of Elderly Patients with Chronic Myeloid Leukemia
40. LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE
41. IS THE SURVIVAL OF PATIENTS WITH ESSENTIAL THROMBOCYTEMIA BETTER IN THE LAST DECADE? RETROSPECTIVE ANALYSIS OF DATABASE OF LATIAL GROUP FOR THE STUDY OF NMP, PH NEGATIVE
42. Observational Study of CML Italian Patients Who Discontinued TKIs
43. A case-control study of the effects of hydroxyurea on circulating cortisol levels in patients with acute myelogenous leukemia and chronic myeloproliferative disorders
44. P112 Gene expression patterns in MDS with del5q before and during lenalidomide treatment
45. P110 Lenalidomide in low and int-1 risk MDS with del5q: efficacy and quality of life
46. P106 High-dose rHuEPO for the treatment of patients with low-risk myelodysplastic syndromes
47. P066 Familiar occurrence of myelodysplastic sydrome with del(5q)
48. P016 Revised WHO 2008 classification of patients with RCUD (refractory cytopenia with unilineage dysplasia)
49. P017 WPSS versus Simplified Myelodysplastic Syndrome Risk Score: which is the best tool for prediction of survival in myelodysplastic patients?
50. P001 Prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.